Arin Nam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7780974/publications.pdf

Version: 2024-02-01

		1163117	1125743	
13	316	8	13	
papers	citations	h-index	g-index	
13	13	13	596	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186.	6.5	90
2	FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 399-409.	4.1	59
3	Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget, 2018, 9, 19793-19806.	1.8	34
4	A Non-genetic Mechanism Involving the Integrin \hat{l}^24 /Paxillin Axis Contributes to Chemoresistance in Lung Cancer. IScience, 2020, 23, 101496.	4.1	27
5	Phenotypic Switching of Na $ ilde{A}$ -ve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine, 2019, 8, 1726.	2.4	26
6	MET receptor in oncology: From biomarker to therapeutic target. Advances in Cancer Research, 2020, 147, 259-301.	5.0	20
7	Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. Journal of Clinical Medicine, 2021, 10, 188.	2.4	14
8	Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules, 2022, 12, 8.	4.0	13
9	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. IScience, 2020, 23, 101692.	4.1	9
10	Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. Journal of Clinical Medicine, 2020, 9, 2433.	2.4	9
11	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 1820-1835.	4.1	9
12	Heuristic value-based framework for lung cancer decision-making. Oncotarget, 2018, 9, 29877-29891.	1.8	5
13	Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. International Journal of Oncology, 2020, 57, 80-86.	3.3	1